Podcasts about t1d

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

Argelis Milian Robles was diagnosed with Type 1 diabetes in 2025 — alone, without a car, on the brink of losing her job, and managing celiac on top of it all. And that was just the beginning. What came next tested everything she had. Her faith. Her will to stay. Her relationship with her own body.In this episode, Argelis opens up about the moments that brought her to her lowest point and what it actually took to start building a life she wanted to live… one that includes pancakes, boba, and yellow curry. It's a story about learning to trust yourself when everything falls apart at once.WHAT WE COVER:The Sunday morning church visit that ended in the ICU with a blood sugar of 407What a pituitary brain hemorrhage six months into T1D changed about her insulin resistance, her mental health, and what she wanted for her lifeHow celiac prepped Argelis to drop her A1C from 13.9 to 5.4 in eight months, and why she doesn't recommend itWhy pancakes, boba, and yellow curry became the goals that mattered most in coachingThe two pages Argelis wrote after the brain hemorrhage that changed the direction of her lifeWHAT'S NEXT:

Tyler Cook is a professional GT3 racing driver who has competed in some of the most grueling endurance races on the planet, the 24 Hours of Spa, the 24 Hours of Nürburgring, IMSA, and GT World Challenge Europe. He's also been living with type 1 diabetes since he was 11 years old. This episode gets into what it actually looks like to manage blood sugar in a fire suit, in a 130-degree cockpit, at 150 miles per hour, sometimes at 3 a.m. Tyler takes us back to his diagnosis in 2006 — an ICU stay, four IVs, and a very specific grief over the chocolate mousse at Epcot's France pavilion. From there, he walks us through the journey from go-karts in his dad's garage to GT3 race cars with 650 horsepower. Along the way, there was bullying in middle school over his diet, sneaking to the bathroom to give injections on dates, and a decision somewhere along the line to stop hiding his diabetes and start owning it. We get into the technical side, too: how OmniPod changed his race management strategy, why adrenaline sends his blood sugar climbing instead of crashing, what a 24-hour-race insulin plan actually looks like, and what it means to have a Gatorade button wired into your cockpit as an emergency low-blood-sugar protocol. Tyler also talks about the physical training side of racing — heart rate zone work, neck day (yes, neck day), and why a GT3 driver can be pressing 1,200 pounds of brake force per pedal. The episode wraps with something that's been sitting with both Rob and Tyler: the idea of trusting the process. For Tyler, the lesson comes through racing — you can't skip steps from spec Miata to GT3. For people with T1D, it's the same. Wherever you are in your management journey, that's where you are — and it's going to get better if you just keep going. Chapters: 00:00 Climbing out of a race car at 2 a.m. 00:51 Introducing Tyler Cook, GT3 driver with T1D 01:52 Diagnosis at 11: ICU, four IVs, and Epcot chocolate mousse 04:16 Go-karts at three, racing in the family DNA 06:20 Racing pre-CGM: going off vibes and feeling lows 07:29 Bullied for his diet in middle school 09:53 Dating with diabetes and deciding to stop hiding it 12:29 Going public: from fear of losing opportunities to advocacy 13:35 A potential cure and why staying healthy now matters 17:19 What GT3 racing actually is — and why you should go watch it 23:02 The Gatorade button: CGM and cockpit glucose management 24:28 130-degree cockpits, adrenaline spikes, and pre-race hydration 25:39 WHOOP strain scores: practice vs. race stint 28:37 Training for the car: heart rate zones, neck day, 1,200-lb brakes 36:45 What Tyler would tell 11-year-old himself: trust the process Resources: * Tyler Cooke Instagram * Breakthrough T1D * Conor Daly (T1D IndyCar driver Tyler mentioned)

Angela Gaeddert was diagnosed with Type 1 diabetes at nine years old. For 23 years, she showed up to her endo appointments and filled in the gaps on her own. Along the way, she navigated diabulimia during one of the most isolating seasons of her life, and more recently, received a diagnosis of diabetic retinopathy.In this episode, Angela shares how her meal spikes went from 220 to 170, her energy from a 5 to a 9, and her self-love and acceptance from a 4 to an 8. But what shifted most was how she sees herself. She shares what it looked like to recover from diabulimia largely on her own, stop comparing to other T1Ds, and finally look for more support.Tune in for an honest, moving conversation about what it looks like to keep going through the hard parts of this disease, and the reminder that it's never too late to reclaim your rise.WHAT WE COVER:How Angela valued feeling thinner more than her T1D during COVID, and the moment she finally put the pieces togetherWhat it felt like to think "anything under 250 was a win" and why that mindset was so hard to move past aloneThe moment Angela looked up at her husband and her vision had completely changed, and what the doctor said nextWhy Angela felt devastated after her retinopathy diagnosis and how she worked through itHow her meal spikes went from 220 to around 170, and what that shifted in her energy and peace of mindWhat finally made her feel like she's one step ahead of T1D.WHAT'S NEXT:

If you've been working harder and harder to improve your blood sugars but still feel stuck, this message is for you.Many people with Type 1 Diabetes hit a point where more effort doesn't create better results—it only creates more frustration and burnout.The breakthrough often comes from strategy, precision, and understanding what's really holding you back.Remember: Sometimes the hose isn't too short... it's just wrapped around the table.Work smarter, not harder. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

“I had no idea adults could get Type 1”. Sue May spent more than 20 years as a health coach supporting women through fertility, IVF, perimenopause, and menopause. But in her 50s, her own life took an unexpected turn when she was diagnosed with type 1 diabetes after missing symptoms like extreme thirst, rapid weight loss, and exhaustion, eventually discovering her blood sugar was over 500.As someone who had spent her career helping others navigate major health transitions, Sue suddenly found herself overwhelmed, under-supported, and trying to make sense of a diagnosis she never saw coming.In this episode, Sue shares what it was really like to be diagnosed later in life, the emotional weight of learning to manage an entirely new condition, and how finding the right support completely changed her experience. She also opens up about the overlap between type 1 diabetes and perimenopause, why so many women are left without answers during hormonal shifts, and what it looks like to advocate for yourself through seasons of change.Tune in to gain a deeper understanding of adult-onset type 1 diabetes, the impact hormones can have on blood sugars, and the reminder that even the most unexpected diagnosis can become an opportunity to reclaim your rise.WHAT WE COVER:How Sue navigated being diagnosed with T1D in her 50sWhy adult-onset type 1 diabetes is far more common than most people realize, and early signs to watch forWhat it means to stay flexible when life, hormones, and diabetes are constantly evolvingSue's reminder that women are not “crazy” when they notice midlife changesHow Sue turned an unexpected diagnosis into a new purpose and a deeper way of serving othersHow finding community helped her stop feeling alone and start feeling empowered in her diabetes journeyWhy reclaiming your rise starts with putting yourself first and trusting your ability to adapt through every seasonWHAT'S NEXT:

 Living with diabetes doesn't have to mean constant highs, lows, and mental exhaustion.In this conversation, a 25-year T1D shares how she went from 60–70% time in range to 78%—and even 95% on easier days—while actually living her life again.Less stress, more energy, and finally space to just be present. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss several major developments in diabetes technology and obesity therapeutics, beginning with Abbott's announcement that its dual glucose-ketone monitoring systems, Libre Duo and Libre Duo 10 Day, have received CE mark approval in Europe. The hosts describe the devices as the first continuous glucose-ketone monitors capable of simultaneously measuring glucose and ketone levels through a single wearable sensor, with real-time ketone monitoring intended to identify rising risk for diabetic ketoacidosis (DKA). Bellini explains the rationale for separate 15-day adult and 10-day pediatric sensors, noting higher sensor failure rates and greater activity levels in children. Both hosts emphasize the potential clinical significance of continuous ketone monitoring, particularly for individuals with type 1 diabetes (T1D) using insulin pumps, where interruptions in insulin delivery can rapidly precipitate DKA.The discussion further explores how continuous ketone monitoring may expand the safe use of SGLT2 inhibitors in people with T1D and other high-risk populations. Bellini highlights concerns surrounding euglycemic DKA associated with SGLT2 inhibitor therapy and suggests that continuous ketone data could help clinicians identify susceptible individuals earlier, potentially enabling safer and more individualized dosing strategies. Isaacs underscores the limitations of current ketone testing methods, particularly urine ketone testing, which she characterizes as outdated and insufficient for modern diabetes management. The hosts also review additional patient populations that may benefit from continuous ketone monitoring, including individuals with recurrent DKA, pediatric patients with highly variable glycemic patterns, and hospitalized patients at elevated risk for ketosis due to prolonged fasting or treatment interruptions.Isaacs and Bellini also consider practical questions surrounding implementation, including reimbursement, cost, workflow integration, and compatibility with automated insulin delivery systems. They discuss whether continuous ketone monitoring could eventually become standard of care in T1D and debate the broader implications of widespread ketone data availability, including potential consumer interest outside traditional diabetes populations. Both hosts stress the importance of prioritizing access for patients at highest risk for DKA while acknowledging that broader adoption could reshape diabetes monitoring paradigms similarly to the evolution of continuous glucose monitoring.The episode then turns to recent reports involving Dexcom sensors that were reportedly stolen after being removed from the manufacturing process for quality concerns. Bellini explains that some of the affected sensors may not have completed sterility and quality assurance procedures before entering secondary markets. The hosts caution clinicians to review affected lot numbers and encourage ongoing vigilance until additional information becomes available. They also discuss the challenges of communicating recalls and safety alerts directly to patients, particularly for users relying on standalone receivers that may not connect to cloud-based notification systems.Finally, Isaacs and Bellini review newly released topline results from the phase 3 TRIUMPH-1 trial evaluating retatrutide, Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Bellini summarizes findings demonstrating substantial weight reduction among adults with obesity or overweight without diabetes, including mean weight loss exceeding 28% at 80 weeks and continued weight reduction through 104 weeks without evidence of plateau. The hosts note that nearly half of participants achieved at least 30% weight loss, approaching outcomes historically associated with bariatric surgery. They also highlight low discontinuation rates and discuss the implications of future TRIUMPH studies evaluating retatrutide in patients with type 2 diabetes and cardiovascular disease. Isaacs concludes that the emerging data signal a transformative shift in obesity treatment, with pharmacologic therapies increasingly approaching surgical efficacy and potentially reshaping long-term obesity management strategies.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Meet our panel of BC mental health providers trained to work with the T1D community from pediatric to adult care. Learn about their services, how to access them, and how they can help you. Speakers' contact information can also be found on Breakthrough T1D Mental Health + Diabetes Directory (https://directory.breakthrought1d.ca/).Over 18 and interested in sharing your experiences living with type 1? Register to attend a live huddle at www.t1dhuddle.com.

In this episode, Meg Bomley shares her T1D journey from being diagnosed at 18 years old and spending eight years on MDI without a CGM, to becoming someone who feels deeply empowered in her body and her diabetes.Meg first came on the podcast in 2022 after graduating from Risely coaching. At the time, she had just come out of a season of constant lows, burnout, and feeling completely overwhelmed after switching to a pump without the support she needed.Today, she's back as a nationally board certified health coach, and 35 weeks pregnant with type 1 diabetes, one of Risely's top coaches.The majority of this conversation is the reality of navigating pregnancy with T1D: the nausea, insulin resistance, fear of highs, changing carb ratios, and learning to trust yourself in this season.WHAT WE COVER:Why Meg resisted pumps and CGMs for nearly 8 years after diagnosisThe “biggest disaster ever” that happened when she first switched to a pumpWhat finally helped her stop feeling resistant, overwhelmed, and burnt out with diabetesHow coaching helped her uncover mindset blocks that had nothing to do with insulin or carb countingThe first sign Meg noticed that told her her insulin resistance was changing after getting pregnantHow she managed nausea, vomiting, insulin on board, and eating mostly carbs during pregnancyThe difference between taking 5 units for oatmeal pre-pregnancy vs. 16 units during pregnancyWhat it's actually like mentally to watch yourself take “large amounts of insulin” every dayWHAT'S NEXT:

 I just had my diabetes supplies changed by insurance without anyone even telling me.No notice. No consent. Just a different order showing up at my door.So I had to call in and figure it out myself.And instead of arguing, I used a few simple psychology-based tactics that completely changed how the conversation went… and I ended up not only fixing the issue, but getting extra supplies approved too.I broke down exactly what I did in this video — step by step — because this is something a lot of people living with diabetes quietly deal with, but don't really talk about. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Thirty-four-year T1D veteran and engineer Arnie discusses offering free diabetes coaching on Instagram , while Scott uncovers the algorithm mechanics behind the "social media casino". Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  ABLEnow save for today's needs or invest for tomorrow Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 20% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Rafael Pepen was diagnosed with Type 1 diabetes at 17, right in the middle of rehearsing for his very first musical in the Dominican Republic. Without access to a CGM or carb counting education, he learned to manage largely on instinct. Years later, he moved to the US, pursued his dream of performing professionally, and eventually landed at Disney, where he now performs five high cardio shows a day.In this episode, Rafael sits down with Lauren to talk about what it actually looks like to manage T1D in a life that never slows down. He shares the months of burnout, panic attacks around lows, and constant roller coaster blood sugars that led him to seek coaching, and what shifted on the other side of that.WHAT WE COVER:What it was like to be diagnosed at 17 in the Dominican Republic with limited access to education, CGMs, or carb counting guidanceThe unique challenge of managing T1D across five high cardio shows a day and why it is a completely different beast from a traditional performance scheduleThe moment things started to unravel at Disney and what five months of daily lows, panic attacks, and burnout actually felt like from the insideWhat shifted when Rafael started working with a Risely coach and the tools that made the biggest difference for his day to day managementThe emotional side of T1D that most people never talk about, including what it felt like to cry during a low and the moment that started to changeWhat Rafael is still working toward and the one thing he wants most from his relationship with diabetes going forwardWHAT'S NEXT:

After 47 years with Type 1 Diabetes, Cathy thought she had already learned everything… until she discovered predictability.

Scott and 23-year-old Bridget discuss her college T1D diagnosis , managing Hashimoto's and ovarian cysts , using Mounjaro , and the mental hurdles of taking daily medications. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

In this solo episode, Lauren breaks down one of the most common and frustrating T1D scenarios: correcting and still running high. She starts by validating why it's so hard, and how it's not necessarily because of the high itself, but because of the "boomerang decision" it creates. Lauren walks through the exact decision framework she uses with clients at Risely to think through this scenario clearly. From checking your insulin timing and ruling out a site issue to widening the lens on what else might be driving resistance. The goal isn't just to fix the high. It's to build the muscle of thinking through situations like this so they get easier every time. She also shares how the Risely app's Decision Domains feature brings this kind of framework to life, with voice notes and written breakdowns for the real scenarios T1Ds face every day.WHAT WE COVER:Why correcting and staying high feels so frustrating and why the gap between what you expected and what happened is the hardest partThe urge to rage bolus, why it backfires, and what to do insteadChecking the timing of your correction and understanding your insulin action windowWhy ruling out a pump site issue comes first, and how to know when changing your site is worth it even if you're not sure it's the problemWidening the lens to consider fat, protein, stress, illness, and sedentary days as hidden drivers of insulin resistanceHow to use movement to activate insulin on board before reaching for moreWhen to look at your correction factors versus treating this as a one-time scenarioHow decision frameworks reduce the energy drain of T1D over time, and how the newly launched Risely app brings this to life through Decision DomainsWHAT'S NEXT:

Let's talk travel! It's that time of year when we start getting ready for family vacations and trips big and small. Whether you're driving to the beach for a long weekend, heading to a week-long family reunion or taking that dream vacation overseas, diabetes makes everything just a little bit more complicated. I'm talking to Sarah Stewart Holland and Nicholas, parents of three boys, one with type 1. Nicholas has put together a great travel guide and we have a helpful and eye opening conversation about taking T1D along for the ride. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out the Holland's travel guide here Learn more about our upcoming in-person events like Moms' Night Out and Club 1921 here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

My guest this week was Nick and Rebecca Roccanti, the founders of Palmr.  Palmr is a Florida family-style clothing brand. Premium clothing made for real life — coordinating looks for every member of the crew, built for the Florida heat and the way Florida families actually live.Raising two T1D warriors in Orlando, they wanted family clothing that actually felt like it was made for the life they live. Premium without being stuffy. Coordinated in a way that the whole family actually asks for. Built for Florida heat and real days. I spoke with Nick about owning Threadbird -an Apparel and merchandise company providing custom screen printing, embroidery, and design services, and being a merch expert for 20+ Years, and what he has learned now, being a small clothing brand owner, and how his experience running Palmr helps him with other small businesses they work with.   Was great listening to Nick and Rebecca share their journey running the brand, and how it started and where it's going.  Lunch with Biggie is a podcast about small businesses and creatives sharing their stories and inspiring you to pursue your passion, with some sandwich talk on the side. Created, edited, and produced in Orlando, FL by Biggie- the owner of the sandwich-themed clothing brand- ⁠⁠Deli Fresh Threads⁠⁠. Palmr Style Social:Website - https://palmrstyle.comFacebook- https://www.facebook.com/palmrstyleYouTube- https://www.youtube.com/@PalmrStyleInstagram- https://www.instagram.com/palmrstyleTikTok- https://www.tiktok.com/@palmrstyleBiggie's Social: ⁠⁠Deli Fresh Thread's Instagram⁠⁠- ⁠⁠https://www.instagram.com/delifreshthreads/Podcast's Instagram⁠⁠- ⁠⁠https://www.instagram.com/lunchwithbiggiePodcast's Facebook Group⁠⁠- ⁠⁠https://www.facebook.com/groups/lunchwithbiggie⁠⁠ ⁠⁠YouTube:  https://www.youtube.com/delifreshthreadsPodcast's Twitter-⁠⁠ ⁠⁠https://twitter.com/LunchwithBiggie⁠⁠ ⁠⁠Deli Fresh Threads⁠⁠- ⁠⁠ ⁠https://DeliFreshThreads.com

100% Time in Range at Disneyland No rigid rules. No perfect conditions. Just learning how to adapt, think critically, and stay one step ahead.Your diabetes shouldn't stop you from living your life. The goal isn't perfection — it's freedom with control. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

We start the show with breaking news regarding the lack of caffeine in Todd's house. We quickly jump into the busy on-goings in Todd's world of late. We hop into a conversation (24:00) about bankruptcy, for some reason and then talk about the best search engines and kid sports. We have a quick T1D convo (52:00) and discuss our very giving Uncle and the gifts he has sent us. Sponsors: ScottyJ's album, Diet Coke, Egg Roll ExpressScotty Js YouTube Page: https://www.youtube.com/channel/UCV3WWSlwDKYf7P5k4XdP3zAIG & Twitter: the_bro_pod, littleBquotesE-mail the show!: thebropodnetwork@gmail.comBuy Merch!!: thebropod.threadless.comOur Website: www.bropodnetwork.com#DietCoke#Frozen#onceremoved#dance#Ryno#BK#soccer#sports#solitaire#earlyend#UncleEddie#CDs#podcasts#bropod#bropodnetwork

Suzanne discusses her 34-year journey with Type 1 diabetes , navigating chronic fatigue syndrome , and the challenges of caring for her 85-year-old mother who also has T1D. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Suzanne returns to discuss managing Addison's disease and T1D, detailing emergency injection protocols and steroid-induced insulin resistance. They also tackle dinner pre-bolusing struggles and diabetes social media burnout. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

What happens in the room when a therapist with Type 1 diabetes hears the same fear over and over, that everyone else has their numbers under control, and you're the only one who doesn't? Rob sits down with Christine Keown, a registered psychotherapist and T1D since age four, to have the conversation that doesn't get nearly enough airtime. Recorded right in the middle of the Diabetes and Mental Health Conference, this one covers a lot of ground and goes places most diabetes content never does. Christine shares what she calls her “meta-analysis” of her clients: the common threads she sees across every person with diabetes who walks through her door. The fear of judgment around numbers. A fractured sense of identity after diagnosis. The compounding spiral of healthcare avoidance. And high-functioning burnout, the kind that looks completely fine at work and only shows up at home. Rob opens up, sharing what a recent diabetes meditation retreat revealed to him about conditional joy, self-compassion, and why he's been sitting with the uncomfortable truth that he's not nearly as in control as he'd like to be. One of the standout moments is Christine's live demonstration of an ACT (Acceptance and Commitment Therapy) exercise using a literal piece of paper. The idea: we exhaust ourselves pushing our fears away. What if we just put them down instead? Rob couldn't stop laughing, and neither could we. This episode is for anyone who has ever felt like they're failing at diabetes, quietly avoided the endocrinologist, or thought everyone else has it figured out except them. You're not alone. Not even a little bit. As Christine and Rob both land on: we're all just doing our best, every single day. Chapters: 00:00: Rob introduces Christine Keown, registered psychotherapist 01:46: Recording live at the Diabetes and Mental Health Conference 02:26: Why people seek out a therapist who also has diabetes 04:01: Fear of judgment keeps people away from community 05:45: When the endocrinologist becomes the threat 06:44: Diabetes distress and physician-related avoidance 07:58: The compounding loop: wanting care, avoiding it anyway 08:58: The therapist's privilege: normalizing what everyone feels 10:27: The meta-analysis: what every T1D client shares 11:11: Fear of comparison and the myth of perfect control 12:36: Conditional joy: happiness gated behind blood sugar 13:37: Christine's pre-podcast low and the reality of T1D 15:13: The messenger matters more than the message 16:23:  A joy shared is a joy multiplied 17:42: Identity shifts after a chronic illness diagnosis 18:15: Christine's story: leg muscles, mountains, and Costco 21:07:  Rob on learning to ‘be' instead of always ‘do' 21:31:  Grief, anxiety, and diabetes pulling us from the present 23:51: ACT therapy: the paper exercise for carrying fear 28:03: Naming the fear instead of making it the main character 30:18: Chronic illness and the desperate need for control 31:08: High-functioning burnout: invisible to everyone around you 32:43: Signs at home no one at work will ever see 34:49: Distraction through overwork and the “next thing” trap 35:30: A call to curiosity, self-compassion, and getting help Resources: * Christine Keown on Instagram: @your_health_therapist * Diabetes & Mental Health Conference: Session recordings still available at dmhconference.com

Diagnosed with T1D 51 years ago , Suzanne discusses her journey with autoimmune stacking. She details a terrifying adrenal crisis that ultimately led to an Addison's disease diagnosis. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more.  Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/   XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community.  It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected   XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌​has approved the first generic ​version of ​Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX  Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D  The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028.   XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage.   Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company's Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it's the episode just before this one. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pumps-over-software-malfunction/818260/   XX Switching CGMs didn't make a measurable difference for adults using MiniMed's pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. "When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more," Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. "Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want." I'm including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery   XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. "More research is needed to see if there are other factors that are associated with risk reduction." https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants   XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world's first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study.   The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can't necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison.   The Virginia senator wrote on the social platform X, "As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we've received. Thank you to everyone for your kind words." Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were "heartbroken beyond words" by their daughter's passing.   On Monday, the former Virginia governor said his daughter "was a deeply empathetic and engaged person" and that "as recently as the day she passed, she was full of ideas and suggestions" for him, including how he could improve his social media presence.   "She used to say to me: 'Dad, you have the power — you have to use it.' She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways," he added.       "If I can find any solace during this time, it's that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy's name."   Warner concluded, "I look forward to returning to the Senate this week and continuing that essential work."   Madison Warner is survived by two younger sisters.     An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC's National Diabetes Statistics Report.   An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes.   Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D.  The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.

About a month ago, Lauren went through a two week stretch of crazy work hours, disrupted sleep, missed workouts, and a few sick days. Her time in range started slipping and she had to figure out how to navigate it in real time.In this solo episode, she walks through exactly what happened, how she recognized her insulin sensitivity was changing, and the three options she always considers when life throws her off routine. Because waiting for perfect conditions to come back is never the answer.WHAT WE COVER:The first sign Lauren noticed that told her her insulin sensitivity was dropping The three options available when your insulin sensitivity changesHow Lauren used a hybrid of all three approaches to get her time in range from 65% back up to 80% during a chaotic two week stretchThe difference between temporary insulin resistance and a long term foundational shift in your sensitivity and how to know which one you are dealing withWhat factortends to creep up when you are out of your routine and how it impacts your insulin sensitivity more than most people realizeHow hormones, sleep, stress, illness, and exercise all play a role in shifting your sensitivity and what to do about each oneWhat parents of children with T1D need to know about insulin sensitivity changes during pubertyWHAT'S NEXT:

 Tomorrow: Disneyland  Tonight: game plan.Type 1 diabetes doesn't mean missing out—it just means being prepared.Not chasing perfect numbers, just control + freedom. Adjust early, stay flexible, enjoy the moment.You don't have to choose between great blood sugars and a great life—you can have both. Keep up the fight. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

On April 30, we celebrated the kickoff of the 5th annual, global Medical Innovation Olympics (register today at https://medicalinnovationolympics.com) with a moving interview in which a 5-Time Olympic Gold Medalist swimmer, Type 1 Diabetes patient advocate and CEO, Anchor Line Sprots, Gary Hall Jr openly shared the devastation he went through losing all his Olympic models, his house and business in the Los Angeles Fires in 2025. He describes how the "fire left some piece of it in his belly" to pursue what he calls a new do-or-die mission for Olympic-adjacent sports to grow their fan engagement, funding, and popularity. In this conversation Gary demonstrates why he is a true leader of the people who fights daily for a bigger purpose, who cares deeply for the plight of the human community, patients. He shares deep reflections that scratch far beneath the surface with a call to action for innovators in tech and healthcare who have sacrificed their own jobs to be rewarded appropriately and aligned with the priorities they deserve in their respective industries - something all of us need to think about and address.Timeline0:00 Episode Introduction1:57 Medicalinnovaitonolympics.com - Sign up for the event2:36 Meaning of 10 replacement medals Gary lost in the LA fires in '255:14 The Real-World Story of the LA Fire Disaster and Devastation6:36 How the IOC presented the replica medals - 2nd time in history after Muhammad Ali7:14 Last time the International Olympic Committee replaced a medal was Muhammad Ali10:10 How Gary as T1Diabetes Patient defines Healthcare ChampionsGary Hall: Medical Innovation Olympics is a Noble Pursuit11:21 Coders like Researchers have built AI that can replace them - Tremendous Sacrifice11:54 How do we realign incentives so that people are rewarded on their sacrifice12:26 Update on the latest research in T1Diabetes - we are on the doorstep14:04 CEO of iTolerance's recent passing & promise of curing T1D without immunosuppression14:53 Gary's opinion on Lindsay Vonn's comeback attempt and fall at Milano Cortina17:06 Milano 2026 Olympic Highlight Alyssa Liu, Figure Skater's Charisma and Embodiment of Joy18:11 Men's Hockey - U.S.A.18:30 Sara Conti, Italian Figure Skating's visible 21:35 Gary Hall's new company, Anchor Line SportsOlympic adjacent sports betting fan engagement tool Olympic sports remain underfunded23:30 U.S. is one of few countries where not one single dollar supports Olympic athletes24:19 Anchor Line Sports is the silver lining Gary took away from losing his house, business, medals27:57 Q & A: Parallels between building championship teams and healthcare companiesThe team is most important and the reflection of the leadership - pushing you to the point of failure every single day in a tough, and are able to do it in a tough, demanding and respectful way. This is exactly what great leaders do in the workplace. They lead by example, and they earn their respect. All ships rise with the tide.30:09 Q & A: Support Gary Hall & Upcoming Announcement from Anchor Line Sports31:14 Public Promise to Gary Hall Jr and Bob Beamon, former world record holder for Medical Innovation Olympics to Leave a Global Legacy 32:32 Gary's Endorsement and Best Wishes for the Growth of Medical Innovation Olympics

In this episode, Lauren walks through a recent day in Florida where a combination of late night pizza, an exhausting night with a newborn, a long tennis session without enough food, and a handful of chips sent her on a full day roller coaster that ended with a scary low at dinner.Lauren shares the five things she always does to reset physically and mentally following a tough blood sugar day, and why how you respond matters just as much as what caused it in the first place.WHAT WE COVER:First and foremost: EVERY T1D has bad blood sugar days, what matters is how you respond How to get to a place where these days are more rare then they are normal   Lauren's five steps for overcoming a bag blood sugar day Why reflecting on these days is important & how to stop procrastinating it Recognizing low TIR days as data to move forward *instead of* a reflection of failure Why communicating with the people around you on bad blood sugar days matters and how to ask for what you actually needWHAT'S NEXT:

When your blood sugar is doing the absolute most and you've already done everything “right”…

Zach discuss the "first hundred days of chaos" following a toddler's T1D diagnosis. Topics include AI diagnosis, IVF background, and managing honeymooning. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  ABLEnow save for today's needs or invest for tomorrow Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 20% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

It's In the News! Every other week we bring you the top diabetes stories and headlines happening now. This week's top stories: stem cell reserach updates, the Pivot patch pump gets FDA approval, GLP-1 Resistance research moves forward, T1D kids in VA get a big win, time of day for exercise matters, and much more! Don't miss our 2026 events - Club 1921 and Moms' Night Out info here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

On April 3rd, in the middle of a regular workday, Lauren's CGM read 245 with double arrows up. She did not feel high. She bolused anyway. Twenty minutes later she was on her kitchen floor, chugging orange juice, with her blood sugar in the 30s, headed down fast. Her CGM had been over 100 points off.In this solo episode, Lauren shares exactly what happened that day, why it scared her in a way that CGM issues never had before, and what she believes needs to change in the conversation around CGM accuracy. She also talks about how to hold gratitude for the technology that keeps us alive while still being honest about its limitations and why trusting your instincts and finger pricking more often might be the most important PSA she can share right now.WHAT WE COVER:How Lauren's CGM was recently over 100 points off, and why it led to one of the worst lows she has had in yearsThe three issues she noticed immediately after switching to the Dexcom G7 last August and how they evolved over timeWhy she believes you can hold gratitude for diabetes technology in one hand and frustration in the other at the same timeWhat she would do differently next timeThe PSA every person with T1D needs to hear about finger pricking and what happens when you override your own instinctsWHAT'S NEXT:

“My blood sugar feels random…”Same food. Same insulin. Different day… different result.It's not random.

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Coach Ken sits down with Lisa Katzenberger to explore what it really looks like to rebuild trust as a T1D parent. Lisa shares her personal journey navigating the emotional challenges that come with being a diabetes caregiver, and her perspective of navigating motherhood to a T1D child. Lisa is also an author and shares her journey in telling the story of how insulin was created - It Belongs to the World: Frederick Banting and the Discovery of Insulin.

Most of us know diabetes affects the body. Fewer of us talk honestly about what it does to the mind and what the mind does right back. In this episode, Rob sits down with Sam Tullman, co-founder and facilitator of Diabetes Sangha and a dedicated student of Rinzai Zen, for a wide-ranging conversation on mental health, mindfulness, and what it actually means to live well with diabetes. Not managing it perfectly. Live well with it. They get into the neuroscience of why checking your CGM makes you hold your breath, why rage bolusing is as much an emotional event as it is a physical one, and how the concept of interoception, your brain's ability to read signals from inside your body, turns out to be both a burden and a hidden advantage of life with type 1. Sam introduces a question that quietly reframes everything: what is your actual goal in living with diabetes? His answer might surprise you. The conversation winds through predictive processing theory, Zen master stories dating back to 17th-century Japan, the research behind mindfulness-based stress reduction, and Rob's own discovery of what he calls "rage gratitude", a practice that started with 35 lines scribbled on a page and changed how he moves through his days. If you've ever wondered whether mindfulness is actually practical for someone who's already managing a chronic illness on top of everything else, this episode makes the case. Sam is also a fellow podcaster and one of the most thoughtful voices in the T1D mental health space. By the time this episode is published, Rob will be sitting with Sam and the rest of Diabetes Sangha at their spring retreat. Which, honestly, feels like the right note to publish on. Chapters:  00:00 Introduction: Sam Tullman and Diabetes Sangha 01:14 Welcome back: catching up since last time 02:03 Mental health as part of the whole body 03:29 How the mind directly impacts blood sugar 04:42 Rage bolusing: a behavioral health problem 07:16 Rob's real-time low and what he noticed 08:58 Predictive processing theory and Dr. Lisa Feldman Barrett 10:12 How the brain makes its best guess 13:03 Interoception: the hidden strength of living with T1D 15:02 Awareness as both burden and advantage 18:33 Holding it in both hands: grief and gratitude together 24:09 Mindfulness as a muscle: how to start building it 25:22 The question that reframes everything: what is your goal? 29:00 Two kinds of meditation practice: relief and long-term growth 31:51 Growth is uncomfortable — and that's okay 36:18 The Zen master Hakuin story 40:34 After ecstasy, the laundry — and changing your CGM 44:44 Rage gratitude: Rob's discovery of a simple practice 47:17 Many paths to the same place: finding what works for you 48:13 Diabetes Sangha: community, retreats, and resources Resources: Diabetes Sangha — weekly meditations, newsletters, events, and retreats for people living with diabetes How Emotions Are Made by Dr. Lisa Feldman Barrett — referenced by Sam on predictive processing theory and interoception Dr. Brad Liechtenstein — retreat facilitator and breath expert mentioned by Sam, works with people with chronic conditions: search "Dr. Brad Liechtenstein" or find him through naturopathic health directories

Erin Provost was living a busy life as a wife and mom when she was diagnosed with Type 1 Diabetes at 30. In 2023, she was diagnosed with breast cancer, and spent the better part of a year fighting her way through it. Just when she thought the hardest part was behind her, a routine eye appointment introduced her to one more word she never expected to hear: retinopathy.In this episode, Erin sits down with Lauren to talk about what it looks like to manage T1D through a cancer diagnosis, radiation, a hysterectomy, and the complete loss of her ability to feel her lows and highs. She talks about the guilt, the burnout, the deep fear of insulin that took root after a terrifying low, and the moment the retinopathy diagnosis finally pushed her to get the support she had been needing. She shares how coaching helped her go from 50% to 75% time in range by taking it one small step at a time, and what it meant to finally stop being angry at herself and start forgiving herself for the years of hardship.WHAT WE COVER:What it felt like to manage T1D while fighting breast cancer, how her A1C climbed to an 8.5 during treatment, and why she does not blame herself for itHow accidentally doubling her metformin dose led to a terrifying low that created a lasting fear of insulin, affecting every bolusing decision she made from that point forwardWhat it was like to lose the ability to feel both lows and highs after a hysterectomy, and how she learned to navigate T1D without any of the physical signals she had relied onThe moment at her eye doctor appointment where she finally decided she could not keep going the way she had been and sought supportHow coaching helped her take one step at a time, starting with something as simple as eating breakfast, and how those small steps compounded into real momentumWhat it means to stop wallowing, forgive yourself for the hard years, and find your way back to yourselfWHAT'S NEXT:

Insulin is slow… but you can make it work faster. If you're living with Type 1, remember this: you have more control than you think.From pre-bolus to simple “accelerators” like walking  or even a hot shower —small actions can make a big difference in your blood sugars.Stop just surviving. Start understanding. Start thriving. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Today on Diabetes Connections.. a bonus episode all about finding support and community online and in real life. Seems to be a theme lately and I could NOT be happier. Type One Together started with one college student, a few babysitting jobs, and a realization that there was a need. Type One Together has become something much bigger – they'll still help you find a sitter but they're also a hub for T1D info, support and gatherings. I'm talking to the founder, Raquel Baron, about how they got there, what kind of help they provide and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Type One Together's events here - use promo code "connections" to save Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

Coach Lindsey has lived with Type 1 Diabetes for 19 years and has been coaching with Risely for over two years. Lindsay was already a health coach in her primary role when she came to Risely as a client. She came through our group coaching program, found her footing with her own diabetes management, and knew she wanted to bring that same support to others. After completing the program, she went on to earn her National Board Certification in coaching and trained under the Risely team before officially joining as a coach. She now works with clients through the exact challenges she once navigated herself, which makes her one of the most grounded voices on what it actually takes to move from reactive management to intentional decision-making with T1D.In this episode, Lauren and Lindsey dig into the Tandem pump features that many T1D's either don't know exist or don't know how to use to their full advantage. They cover the features most people are only using at surface level (Control IQ, sleep mode, exercise mode, temp basal, and extended bolus) and share the real-life context behind when and why to use each one. The conversation is honest about the fact that none of these are one-size-fits-all, and that getting to a place where these tools feel second nature takes time, pattern recognition, and a willingness to test and learn.WHAT WE COVER:The biggest gaps we see when people are using pumps but not actually optimizing themHow to think about your pump as a tool you can adjust, not something that controls youThe difference between reacting to your numbers and making intentional decisionsWhat Control IQ is actually doing in the background, including correction limits most Tandem users aren't aware ofHow to use exercise mode and sleep mode beyond their intended use to help prevent highs and lowsWHAT'S NEXT:

 CGM says “double arrows down” while driving… what would you do?  Most people panic… but there's a better way. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Rob Howe has lived with type 1 diabetes for 21 years. So when he sat down to interview Claude as a newly diagnosed patient, he expected a pop quiz. What he did not expect: Claude passing the test on the first try by answering as Rob himself. Because Claude thought it been hosting this show all along. This is Diabetics Doing Things Episode 348: Claude vs T1D — an experiment in AI health literacy, a genuinely funny accident, and a real question about what AI-powered diabetes care means for everyone. Guest Bio Claude is Anthropic's large language model and this episode's unusual guest. Rob runs the interview twice: first with his regular Claude (which has absorbed 21 years of his diabetes story and all DDT content), then in an incognito window with a clean slate. The contrast is the episode. Key Topics and Timestamps 1:43 — Why Rob is interviewing AI: the Bernie Sanders moment and the AI zeitgeist of early 2026 2:53 — Round 1 begins: Rob plays newly diagnosed patient, Claude plays diabetes educator 7:07 — The plot twist: Claude reveals it has had T1D for 21 years and started Diabetics Doing Things 8:56 — Rob catches it: Thats my LLM. Resets to incognito mode. 9:30 — Round 2: Fresh Claude, no prior context, same 10 questions 10:37 — Claude covers patient assistance programs, 340B pharmacies, free insulin for the uninsured 13:40 — What you actually cannot do with T1D (shorter list than most people think) 17:22 — The reveal: I have had T1D for 21 years. I think you passed. 18:30 — Robs closing question: Is AI advancing faster than humans on diabetes care? Notable Quotes Okay, I have got to stop Claude there — because clearly that Claude is me. — Rob Howe I started Diabetics Doing Things because I realized there was not enough honest conversation about living with type one — the medical stuff, but the real life stuff, the mental load, the wins, all of it. — Claude (Round 1, in Robs voice) Is the future of diabetes care, no matter who you are or where you are, made better by AI? Really something to think about. — Rob Howe, closing From there, the conversation gets tactical and evidence-driven: why breathing is uniquely powerful because it's both autonomic and voluntary, how airflow through the nose can influence brain activity and calm states, and how slow breathing can improve markers tied to autonomic function (like heart rate variability and baroreflex sensitivity) that are often reduced in people with diabetes. Rob connects this to modern diabetes stress—constant data, alerts, and decision fatigue—and why breath is a fast, accessible tool for resilience. Nick addresses the “woo vs. science” tension by grounding claims in research and meta-analyses while staying open to whatever “gateway” gets someone to practice safely. They close with simple starting protocols (using an app, 4-in/6-out pacing, diaphragmatic breathing), and emphasize nasal breathing and mouth taping at night as high-leverage habits—“passive income of health”—with a reminder to keep it safe and consistent over perfection. Chapters: 00:15 Insulin Sensitivity Playbook + Meet “The Breathing Diabetic” 01:27 Diagnosis Story: Age 11, DKA, and the “Diet Coke” Moment 02:48 The “Second Diagnosis”: Mid-20s Wake-Up and Lifestyle Control 03:58 From Air Quality Scientist to Breath Nerd: Discovering Wim Hof 04:51 The Oxygen Advantage: Nasal Breathing, CO₂, and a Breakthrough 08:52 Breath Goes Mainstream: James Nestor Validation + Confidence to Share 11:50 Why Breath Is a Superpower: Autonomic + Voluntary = A Lever 15:11 The Brain Angle: Nasal Airflow, Brainwaves, and Calm States 18:06 Diabetes Physiology: HRV, Baroreflex, and Slow Breathing Benefits 35:52 Practical Protocols: 5-Min Minimum Dose, Apps, Ratios, Mouth Tape Resources: The Breathing Diabetic Instagram The Breathing Diabetic Website

There's a reason we don't call it juvenile diabetes anymore. We all know you grow up and T1D doesn't go anywhere, and that you can be diagnosed at any age. But it often feels like adults are forgotten. I hope that's not the case here—but I hear it all the time in the broader community. Kelly Dawes is working to change that. She's started GrownUp T1Ds, a community built specifically for adults who've been living with type 1 for years and are finally finding connection, understanding, and support in a way they may never have had before. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Grownup T1Ds here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

Many challenges with your blood sugars can be grouped into one of the two categories: habit or infrastructure. Until you know which one you're dealing with, you're likely doing patchwork (making changes that don't move the needle) and getting frustrated by nothing really changing.In this solo episode, Lauren breaks down the foundational framework she uses with every coaching client to identify exactly where the leaks are coming from. She walks through what falls under each category, why most people are unknowingly mixing the two up, and why that's one of the most common reasons people struggle to improve their blood sugars. She also covers the three most important things to understand about how habits and infrastructure interact, why 98% of people who come into coaching are convinced their settings are fine until they actually test them, and the specific order Lauren recommends starting with, so you can build momentum and start making changes that actually move your numbers.WHAT WE COVER:The ship leaks analogy…. why patching what you can see on the surface never works if you haven't found where the water is actually drainingWhat falls under the habit category What falls under the infrastructure category Why the most common mistake is treating a habit issue with an infrastructure change (and vice versa) and the real-life examples that show why this keeps people stuckWhy 98% of people who come into coaching are convinced their settings are fine and what they find when they actually test themHow to tell whether what you're experiencing is situational or a broader sign that your foundation needs to be strengthened WHAT'S NEXT:

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

Megan O'Neill is a physician associate who spent years in clinical practice before finding her calling at the intersection of diabetes care and psychology. While working at the University of Kansas Medical Center, Megan discovered the work of leading diabetes psychology researchers and it changed her entire practice, her perspective, and her passion. That foundation eventually led her to Abbott Diabetes Care, where she has spent the last eight years advocating for the emotional and psychological side of living with diabetes to be treated with the same seriousness as the clinical data.In this conversation, Lauren and Megan dig into what diabetes distress actually looks like day to day — the exhaustion, the isolation, the feeling of doing everything right and still not getting the results you hoped for. They talk about why it often goes unrecognized in clinical care, how it differs from depression, and why a good A1C doesn't always mean you're okay. They also explore how CGMs can both reduce and sometimes complicate our emotional relationship with diabetes and what it actually takes to move the needle when distress is high.WHAT WE COVER:What diabetes distress really is, how it differs from depression, and why it is still significantly underutilized as a screening tool in clinical careWhy people with an A1C under 7 can still score in the moderate to high range on the diabetes distress scale and what that actually meansThe unequal energy exchange of T1D: putting in the effort but not getting the results, and why that cycle is so defeatingHow CGMs have overwhelmingly helped reduce distress and the honest acknowledgment that alarms and constant data can also add to it for some peopleWhat the research actually says about what helps most when someone is not reaching their diabetes goals: it is not just education or medication management aloneThe one tangible step you can take in the next 24 hours if any of this conversation resonated with youWHAT'S NEXT:

Comedian Sam Morrison shares his adult T1D diagnosis, managing ADHD, dating with diabetes, and how a low blood sugar seagull attack inspired his hit solo comedy show, Sugar Daddy. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

Britney discusses her son's T1D diagnosis, the importance of flexible insulin management, and using Trio. Plus, Scott unveils new calculators for baseline insulin settings and the Warsaw method. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!